TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38662979

Group type: EXPERIMENTAL
Intervention: Vidofludimus calcium 10 mg
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Vidofludimus calcium 30 mg
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Vidofludimus calcium 45 mg
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Any dose of vidofludimus calcium
Number of subjects: 268
Study: 38662991

Group type: EXPERIMENTAL
Intervention: ibrutinib 560 mg and venetoclax 400 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Elective treatment interruption (ETI) for patients in MRD-negative CR
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Retreatment after disease recurrence
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Time-to-treatment failure (TTF)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Long-term treatment with venetoclax-ibrutinib
Number of subjects: 24
Study: 38663455

Group type: EXPERIMENTAL
Intervention: IFN + NAs
Number of subjects: 196

Group type: COMPARATOR
Intervention: NAs
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: New scoring system
Number of subjects: 196
Study: 38663470

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 2281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2281
Study: 38663539

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 1.5 mg (LNG1X)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 3.0 mg (LNG2X)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Ulipristal acetate 30 mg (UPA)
Number of subjects: 488
Study: 38663582

Group type: EXPERIMENTAL
Intervention: Individualised, escalated fraction dose of radiotherapy (24 x 3.0-5.4 Gy) with either sequential or concurrent chemoradiotherapy, or radiotherapy only.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (not specified in detail, but implied to be standard treatment without dose escalation).
Number of subjects: 102
Study: 38663902

Group type: EXPERIMENTAL
Intervention: Days with moderate to severe headache
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Days with mild headache
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Days with no headache
Number of subjects: 720
Study: 38663903

Group type: EXPERIMENTAL
Intervention: ICHD-3 criteria for idiopathic intracranial hypertension headache
Number of subjects: 0
Study: 38663908

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 86
Study: 38663950

Group type: EXPERIMENTAL
Intervention: Total carrageenans (100 mg per day)
Number of subjects: 104139

Group type: EXPERIMENTAL
Intervention: Carrageenans gum (E407, 100 mg per day)
Number of subjects: 104139

Group type: EXPERIMENTAL
Intervention: Tripotassium phosphate (E340, 500 mg per day)
Number of subjects: 104139

Group type: EXPERIMENTAL
Intervention: Acetyl tartaric acid esters of monoglycerides and diglycerides of fatty acids (E472e, 100 mg per day)
Number of subjects: 104139

Group type: EXPERIMENTAL
Intervention: Sodium citrate (E331, 500 mg per day)
Number of subjects: 104139

Group type: EXPERIMENTAL
Intervention: Guar gum (E412, 500 mg per day)
Number of subjects: 104139

Group type: EXPERIMENTAL
Intervention: Gum arabic (E414, 1000 mg per day)
Number of subjects: 104139

Group type: EXPERIMENTAL
Intervention: Xanthan gum (E415, 500 mg per day)
Number of subjects: 104139
Study: 38664002

Group type: EXPERIMENTAL
Intervention: VLNC messages (n=468)
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: E-cigarette messages (n=484)
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: Combined VLNC and e-cigarette messages (n=476)
Number of subjects: 971

Group type: COMPARATOR
Intervention: Control condition (water ads, n=473)
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: VLNC messages (n=468) among adults who dual used
Number of subjects: 971
Study: 38664019

Group type: EXPERIMENTAL
Intervention: Prostate-specific membrane antigen (PSMA) PET/CT before definitive radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Definitive radiotherapy
Number of subjects: 0
Study: 38664311

Group type: EXPERIMENTAL
Intervention: Pedicled, autologous temporoparietal fascial flap (TPFF) or pericranial flap (PCF) lining the resection cavity after maximal surgical resection of GBM.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pedicled, autologous TPFF/PCF lining the resection cavity after maximal surgical resection of GBM.
Number of subjects: 12
Study: 38664404

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 0
Study: 38664577

Group type: COMPARATOR
Intervention: FLOX regimen (control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alternating two cycles of FLOX and nivolumab (experimental group)
Number of subjects: 80
Study: 38664620

Group type: EXPERIMENTAL
Intervention: Multimodal primary prevention programme (n=127)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Usual care (n=128)
Number of subjects: 255
Study: 38664665

Group type: EXPERIMENTAL
Intervention: Enhanced study arm with Boot Camp Translation (BCT) materials
Number of subjects: 82

Group type: COMPARATOR
Intervention: Non-local materials
Number of subjects: 82
Study: 38664701

Group type: EXPERIMENTAL
Intervention: Pharmacist-led education according to the AR-PRISE model
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard pharmaceutical care
Number of subjects: 154
Study: 38664706

Group type: EXPERIMENTAL
Intervention: Magnitude ratio variables (ln[affected side magnitude/less-affected side magnitude])
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hierarchical clustering analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Principal component 2 (magnitude ratio domain)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Principal component 1 (activity time and distance component)
Number of subjects: 0
Study: 38664715

Group type: EXPERIMENTAL
Intervention: Kids SIPsmartER intervention
Number of subjects: 526

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 526
Study: 38664766

Group type: EXPERIMENTAL
Intervention: MTX plus corticosteroids (5 mg/m2 methotrexate)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Corticosteroids alone (control group)
Number of subjects: 157
Study: 38664809

Group type: EXPERIMENTAL
Intervention: Vapor barrier with active heating source
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (without vapor barrier)
Number of subjects: 16
Study: 38664811

Group type: EXPERIMENTAL
Intervention: Dynamic flexion to extension cinematographic recordings of the cervical spine (T1 and T2 recordings with a 2-to-4-week interval)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Segmental range of motion (sRoM) and total range of motion (tRoM) measurements
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Correlation analysis between sagittal alignment, degeneration and sRoM
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Correlation analysis between cervical lordosis and tRoM
Number of subjects: 10
Study: 38664919

Group type: EXPERIMENTAL
Intervention: Intervention 1 (default bias and implementation intention)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Intervention 2 (availability bias and social norm)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: General finding
Number of subjects: 229
Study: 38665252

Group type: EXPERIMENTAL
Intervention: Combination naltrexone (NTX) and oral bupropion (BUP)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study: 38665302

Group type: EXPERIMENTAL
Intervention: Mango Leaf Extract (MLE) 300 mg
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 38665614

Group type: EXPERIMENTAL
Intervention: Younis multivariate score (low score ≤14)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Younis multivariate score (high score >14)
Number of subjects: 292
Study: 38665889

Group type: EXPERIMENTAL
Intervention: Wearable devices monitoring in the more severe group
Number of subjects: 98

Group type: COMPARATOR
Intervention: Wearable devices monitoring in the milder group
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Monitoring heart rate-related parameters post-discharge
Number of subjects: 98
Study: 38666065

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38666252

Group type: EXPERIMENTAL
Intervention: High IFABP group (75th percentile)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low IFABP group (25th percentile)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Effects through IL-6
Number of subjects: 50
Study: 38666789

Group type: EXPERIMENTAL
Intervention: Cell Saver group
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study: 38668005

Group type: EXPERIMENTAL
Intervention: Oral care foams
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral care spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no oral care product)
Number of subjects: 0
Study: 38668642

Group type: EXPERIMENTAL
Intervention: Directional deep brain stimulation (DBS) of the VP thalamus
Number of subjects: 6
Study: 38668732

Group type: EXPERIMENTAL
Intervention: Family-focused nurse-led postdischarge intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard follow-up
Number of subjects: 110
Study: 38668797

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle intervention (NOURISH-T+), targeting physical activity (PA)
Number of subjects: 146
Study: 38668988

Group type: EXPERIMENTAL
Intervention: Persistent disturbed somatosensory functioning group
Number of subjects: 223

Group type: COMPARATOR
Intervention: Normal somatosensory functioning group
Number of subjects: 223

Group type: COMPARATOR
Intervention: Recovered somatosensory functioning group
Number of subjects: 223
Study: 38669053

Group type: EXPERIMENTAL
Intervention: Avelumab 800 mg + chemotherapy (cisplatin + gemcitabine)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Avelumab 1,200 mg + chemotherapy (cisplatin + gemcitabine)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Avelumab 800 mg + chemotherapy (carboplatin + pemetrexed)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Avelumab 1,200 mg + chemotherapy (carboplatin + pemetrexed)
Number of subjects: 35
Study: 38669062

Group type: EXPERIMENTAL
Intervention: Text message
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Online (videos, voice notes, online forums)
Number of subjects: 816

Group type: COMPARATOR
Intervention: No interest/skipped
Number of subjects: 816
Study: 38669064

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 0
Study: 38669073

Group type: EXPERIMENTAL
Intervention: web-app intervention
Number of subjects: 1187
Study: 38669315

Group type: EXPERIMENTAL
Intervention: Alemtuzumab and cyclosporine (AC; n = 44)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Tacrolimus, methotrexate, and sirolimus (TMS; n = 39)
Number of subjects: 83
Study: 38669351

Group type: EXPERIMENTAL
Intervention: Tested for inherited thrombophilia (IT)
Number of subjects: 103818

Group type: COMPARATOR
Intervention: Untested for inherited thrombophilia (IT)
Number of subjects: 103818

Group type: EXPERIMENTAL
Intervention: IT-negative patients with surgically provoked VTE
Number of subjects: 103818

Group type: EXPERIMENTAL
Intervention: IT-negative patients with immobilization-related VTE
Number of subjects: 103818

Group type: EXPERIMENTAL
Intervention: IT-negative patients with pregnancy or postpartum-related VTE
Number of subjects: 103818

Group type: EXPERIMENTAL
Intervention: Patients with unprovoked VTE testing positive for IT
Number of subjects: 103818
Study: 38669354

Group type: EXPERIMENTAL
Intervention: 150 mg of L9LS
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 300 mg of L9LS
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 38669533

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 417
Study: 38669626

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (O)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Rituximab (R)
Number of subjects: 85
Study: 38669629

Group type: EXPERIMENTAL
Intervention: roVEMP
Number of subjects: 89

Group type: COMPARATOR
Intervention: SFEMG
Number of subjects: 89

Group type: COMPARATOR
Intervention: Other diagnostic tests (except for the ice pack test)
Number of subjects: 89
Study: 38669634

Group type: EXPERIMENTAL
Intervention: Microglia density in NT1
Number of subjects: 41

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 41
Study: 38669638

Group type: EXPERIMENTAL
Intervention: Erenumab (140 mg once monthly for 3 years)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo followed by Erenumab (140 mg once monthly for 3 years)
Number of subjects: 240
Study: 38669678

Group type: EXPERIMENTAL
Intervention: Mi Sleep Coach app
Number of subjects: 30
Study: 38669706

Group type: EXPERIMENTAL
Intervention: Early cranioplasty (≤ 90 days)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Delayed cranioplasty (> 90 days)
Number of subjects: 173
Study: 38670135

Group type: EXPERIMENTAL
Intervention: Odevixibat 120 μg/kg per day
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 38670326

Group type: EXPERIMENTAL
Intervention: Hybrid Cardiac Rehabilitation (HYCR)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Facility-Based Cardiac Rehabilitation (FBCR)
Number of subjects: 282
Study: 38670537

Group type: EXPERIMENTAL
Intervention: TQB3616
Number of subjects: 0

Group type: COMPARATOR
Intervention: palbociclib
Number of subjects: 0

Group type: COMPARATOR
Intervention: abemaciclib
Number of subjects: 0
Study: 38670599

Group type: EXPERIMENTAL
Intervention: Acyclovir therapy (specific dosage and duration not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific treatment not mentioned)
Number of subjects: 0
Study: 38670604

Group type: EXPERIMENTAL
Intervention: Consensus achieved through multiple choice questions (MCQs) or 7-point Likert-scale statements in Delphi rounds.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Delphi rounds conducted until stable agreement or disagreement is achieved for all statements.
Number of subjects: 35
Study: 38670610

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone
Number of subjects: 75

Group type: COMPARATOR
Intervention: Intravenous immunoglobulins
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Oral glucocorticoids
Number of subjects: 75
Study: 38670616

Group type: EXPERIMENTAL
Intervention: Basic level data obtained from medical records and questionnaires (partner)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basic level data and additional data including questionnaires (mother and partner) and blood samples (all)
Number of subjects: 0
Study: 38670622

Group type: EXPERIMENTAL
Intervention: Respiratory pathogen panel assay (BIOFIRE Respiratory Panel 2.1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group not explicitly mentioned)
Number of subjects: 0
Study: 38670743

Group type: EXPERIMENTAL
Intervention: AI-assisted reading
Number of subjects: 133

Group type: COMPARATOR
Intervention: Standard reading
Number of subjects: 133
Study: 38670789

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery plus alteplase (MIS+alteplase)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: MIS+alteplase
Number of subjects: 310
Study: 38670986

Group type: EXPERIMENTAL
Intervention: Nutritional, water, sanitation, and handwashing (N+WSH) intervention group
Number of subjects: 759

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 759
Study: 38671062

Group type: EXPERIMENTAL
Intervention: Chronically implanted brain-computer interface (BCI) using recurrent neural networks to synthesize speech from ECoG signals.
Number of subjects: 1
Study: 38671174

Group type: COMPARATOR
Intervention: Non-smoking patients
Number of subjects: 320

Group type: COMPARATOR
Intervention: Smoking patients
Number of subjects: 320

Group type: COMPARATOR
Intervention: Vaping/hookah-smoking patients
Number of subjects: 320
Study: 38671251

Group type: EXPERIMENTAL
Intervention: Remimazolam, bolus dose starting at 0.3 mg·kg
Number of subjects: 25
Study: 38671294

Group type: EXPERIMENTAL
Intervention: SUDD
Number of subjects: 266

Group type: COMPARATOR
Intervention: PD
Number of subjects: 266
Study: 38671361

Group type: EXPERIMENTAL
Intervention: Diazoxide choline extended-release (DCCR) tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: PATH for PWS natural history study cohort
Number of subjects: 0
Study: 38671470

Group type: EXPERIMENTAL
Intervention: CHW-led SBIRT intervention plus Alive!
Number of subjects: 440

Group type: COMPARATOR
Intervention: Usual care arm (CRC prevention educational pamphlets and a list of CRC screening sites)
Number of subjects: 440
Study: 38671485

Group type: EXPERIMENTAL
Intervention: ActiGraph activity counts during activPAL-identified sitting events
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: First subject-level PC scores
Number of subjects: 314
Study: 38671587

Group type: EXPERIMENTAL
Intervention: tislelizumab + chemotherapy
Number of subjects: 263

Group type: COMPARATOR
Intervention: placebo + chemotherapy
Number of subjects: 263
Study: 38672206

Group type: EXPERIMENTAL
Intervention: Temporary, silicone-based sealing disc
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study: 38672531

Group type: EXPERIMENTAL
Intervention: Bortezomib addition to standard chemotherapy
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: High expression of 16 histone- and chromatin-modifying enzymes (HMEs)
Number of subjects: 483
Study: 38674674

Group type: EXPERIMENTAL
Intervention: LT-expressing enterotoxigenic intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38674803

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) for 6 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo capsules for 6 months
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 28
Study: 38675738

Group type: EXPERIMENTAL
Intervention: TAPCells-based vaccination therapy
Number of subjects: 0
Study: 38675784

Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine (Sinovac Biotech), administered to indigenous Brazilian individuals between February 2021 and June 2021.
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine (Sinovac Biotech), administered to indigenous Brazilian individuals.
Number of subjects: 328
Study: 38676324

Group type: EXPERIMENTAL
Intervention: Electrical dry needling and thrust manipulation plus multimodal physical therapy
Number of subjects: 143

Group type: COMPARATOR
Intervention: Multimodal physical therapy alone
Number of subjects: 143
Study: 38676659

Group type: EXPERIMENTAL
Intervention: Cat food containing anti-Fel d 1 IgY antibodies
Number of subjects: 49
Study: 38676683

Group type: EXPERIMENTAL
Intervention: Divozilimab (DIV) 500 mg
Number of subjects: 338

Group type: COMPARATOR
Intervention: Teriflunomide (TRF) 14 mg
Number of subjects: 338
Study: 38676748

Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery (Versius® system)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 60
Study: 38676860

Group type: EXPERIMENTAL
Intervention: VenaSeal™ device for cyanoacrylate glue (CAG) ablation
Number of subjects: 70
Study: 38677096

Group type: EXPERIMENTAL
Intervention: Saliva-based microRNA signature for SPE phenotype
Number of subjects: 200
Study: 38677235

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Intervention (FREE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Attention Control (Diabetes Education)
Number of subjects: 50
Study: 38677300

Group type: COMPARATOR
Intervention: No antiviral drugs
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted nirmatrelvir
Number of subjects: 1262
Study: 38677302

Group type: EXPERIMENTAL
Intervention: Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd)
Number of subjects: 50
Study: 38677468

Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy (iNPWT)
Number of subjects: 133
Study: 38677478

Group type: EXPERIMENTAL
Intervention: BEEF
Number of subjects: 16

Group type: COMPARATOR
Intervention: PLANT
Number of subjects: 16
Study: 38677714

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum subsp. longum
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Bifidobacterium adolescentis
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Early antibiotic exposure
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Delivery mode
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Feeding mode
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Introduction of solid food and cessation of breastfeeding
Number of subjects: 196
Study: 38677720

Group type: EXPERIMENTAL
Intervention: OP-724 intravenous infusion at doses of 140 or 280 mg/m
Number of subjects: 5
Study: 38678093

Group type: EXPERIMENTAL
Intervention: R-HAD + B (rituximab, high-dose cytarabine, dexamethasone with bortezomib)
Number of subjects: 128

Group type: COMPARATOR
Intervention: R-HAD (rituximab, high-dose cytarabine, dexamethasone without bortezomib)
Number of subjects: 128
Study: 38678216

Group type: EXPERIMENTAL
Intervention: NavSTAR intervention
Number of subjects: 400

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 400
Study: 38678241

Group type: EXPERIMENTAL
Intervention: Sport climbing (12-week, 90-min-per-week course)
Number of subjects: 48
Study: 38678451

Group type: EXPERIMENTAL
Intervention: 38% SDF gel and 2.5% sodium fluoride varnish
Number of subjects: 237
Study: 38678525

Group type: EXPERIMENTAL
Intervention: BC Chemo
Number of subjects: 642

Group type: COMPARATOR
Intervention: BC Control
Number of subjects: 642

Group type: COMPARATOR
Intervention: NC Control
Number of subjects: 642
Study: 38678757

Group type: EXPERIMENTAL
Intervention: iNAP® Sleep Therapy System
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 63
Study: 38679035

Group type: EXPERIMENTAL
Intervention: Vaccinee group (tetravalent dengue purified inactivated vaccine prime followed by live-attenuated vaccine boost)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (unvaccinated flavivirus-naive participants)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vaccinee group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10